Pancreatic Cancer Research

Clinical trialPhase 1Terminated

FAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients With Select Solid Tumors (FRONTIER)

Outcome
Stopped earlyBusiness decision (Business decision)
Phase
Phase 1
Status
Terminated
Study type
Interventional
Start
13 July 2022
Ended
2 October 2024
Enrollment
20 participants
Sites
4
Primary outcomes
Treatment emergent adverse events
Sponsor type
Industry
Results posted
No
Last update
25 June 2025

These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.

Try

Source text

Brief summary public domain (ClinicalTrials.gov)

This Phase 1 study will evaluate the safety and tolerability of \[Ga-68\]-PNT6555 and \[Lu-177\]-PNT6555 in subjects with select solid tumors that have FAP over-expression, in order to determine a recommended Phase 2 dose.

Intervention public domain (ClinicalTrials.gov)

Drug: [Ga-68]-PNT6555. \[Ga-68\]-PNT6555 IV administered as imaging agent for PET/CT

Intervention public domain (ClinicalTrials.gov)

Drug: [Lu-177]-PNT6555. Patients with FAP-avid disease as determined by the \[Ga-68\]-PNT6555 screening PET/CT will receive \[Lu-177\]-PNT6555 at a fixed dose level for up to 6 doses at an interval of 6 weeks between each dose.

Arm public domain (ClinicalTrials.gov)

Dose escalation (experimental): Up to 30 patients with FAP-avid solid tumors.

Primary outcome public domain (ClinicalTrials.gov)

Treatment emergent adverse events. Occurrence of Treatment emergent adverse events as per CTCAE v5.0 Time frame: From first dose of study drug through end of treatment (~24 weeks).

Secondary outcome public domain (ClinicalTrials.gov)

Adverse events for [Ga-68]-PNT6555. Time frame: From first dose of imaging study drug through 7 days post dose.

Secondary outcome public domain (ClinicalTrials.gov)

Biodistribution and radiation dosimetry of [Lu-177]-PNT6555 to normal organs.. Time frame: From first dose of study drug through end of treatment (~24 weeks).

Secondary outcome public domain (ClinicalTrials.gov)

Biodistribution and radiation dosimetry of [Ga-68]-PNT6555 to normal organs.. Time frame: From first dose of imaging study drug through 7 days post dose.

Secondary outcome public domain (ClinicalTrials.gov)

Detection of [Ga-68]-PNT6555 in tumor lesions. Time frame: From first dose of imaging study drug through 7 days post dose.

Secondary outcome public domain (ClinicalTrials.gov)

Uptake of [Ga-68]-PNT6555 in tumor lesions. Time frame: From first dose of imaging study drug through 7 days post dose.

Eligibility public domain (ClinicalTrials.gov)

Inclusion Criteria: 1. Adult (\>18 years) male and female patients 2. Females of childbearing potential and males and their female partner(s) of childbearing potential must use two acceptable forms of contraception, one being a barrier method, during the study and also for 31 weeks (females) or 18 weeks (males) after last study drug administration. 3. Patients are willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations 4. The patient has read, understood, and signed the written informed consent form(s) 5. Advanced or metastatic solid tumor that is refractory to standard treatment, for which no standard treatment is available, or it is contraindicated, or the patient refuses standard therapy: * Adenocarcinoma of the Pancreas * High grade Soft Tissue Sarcoma (excluding Chordoma) * Esophageal Cancer (Squamous Cell Carcinoma or Adenocarcinoma, excluding Gastroesophageal Junction Cancer at US sites only) * Colorectal Cancer * Melanoma Skin Cancer * Head and Neck Squamous Cell Carcinoma (oral cavity, oropharynx, hypopharynx, nasopharynx, and larynx) (only at Canadian sites) * Cholangiocarcinoma (only at Canadian sites) 6. Laboratory values at initial screening and also within three days prior to dosing of \[Lu-177\]-PNT6555: 1. Platelets greater than 120,000/ mm\^3 at dosing. Transfusions allowed, but not for first dose 2. Neutrophils greater than 1500cells/mm\^3 3. Hemoglobin: * Greater than 8.0 g/dL (only in Canada) * Greater than 8.5 g/dL (only in US) 4. Liver Chemistries: * ALT and AST \< 2.5 x ULN or \< 5 x ULN for patients with liver metastases * Bilirubin \< 2 mg/dL (\<34.2 µmol/L); patients with Gilbert's syndrome are permitted if bilirubin is \< 3 mg/dL (\< 51.3 µmol/L) (only in Canada). * Total Bilirubin ≤ 1.5 x upper limit of normal (ULN); Total bilirubin ≤ 3 ULN is acceptable if a patient has Gilbert's provided that direct bilirubin ≤ 1.5 ULN (only in US) 5. Normal PT(secs) and aPTT(sec); normal INR (ratio). Patients taking anticoagulants must be in therapeutic range 7. Glomerular filtration rate defined as creatinine clearance \>60 ml/min/1.73 m2 based on Cockcroft-Gault formula 8. Life expectancy of at least 6 months per investigator judgement 9. Eastern Cooperative Oncology Group (ECOG) 0 to 1 10. Patients must have previously received treatment for their underlying disease and have no potentially curative options available 11. Positive \[Ga-68\]-PNT6555 …

Enrollment public domain (ClinicalTrials.gov)

Enrollment: 20 participants (actual).

Why stopped public domain (ClinicalTrials.gov)

Business decision